SI-BONE, Inc. SIBN

FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density boneSANTA CLARA, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the iFuse Granite Onyx System (Onyx). This is SI-BONE’s first product addressing the problem of compromised bone which

SANTA CLARA, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming 2026 Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY. Management will be hosting a fireside chat on Monday, September 14, 2026, at 8:30 a.m. Pacific Time/ 11:30 a.m. Eastern Time. Investors interested i

Moby summary of SI-BONE, Inc.'s Q2 2026 earnings call

SI-BONE Inc (SIBN) delivers 15% revenue growth, narrows net loss, and raises full-year guidance on robust procedure volume and promising reimbursement tailwinds.

Si-Bone (SIBN) delivered earnings and revenue surprises of +40.00% and +1.98%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Delivered ~15% WW revenue growth and ~178% increase in adjusted EBITDA ~19% increase in U.S. physician base Second Quarter 2026 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $56.0 million, representing growth of 15.2%U.S. revenue of $53.2 million, representing growth of 14.7%Gross margin of 79.5%Net loss of $4.1 million, representing an improvement of 33.6%Positive adjusted EBITDA of $2.8 million, an improvement of 178.0%Positive cash from operations of

SANTA CLARA, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the second quarter of 2026 after market close on Monday, August 3, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time Investors interested in listening to the conference call may do so by r

Ian Wells, former Global Chief Financial Officer of HOYA Vision Care, appointed CFO, bringing multi-billion-dollar P&L leadership and capital-markets disciplineTom West, who led Intersect ENT to its $1.1 billion acquisition by Medtronic and Nalu Medical to its $600 million acquisition by Boston Scientific, joins as an Independent Board MemberAppointments build the financial and governance foundation for ViCentra’s next phase, following the recent scale-up of commercial manufacturing UTRECHT, The

SANTA CLARA, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming 2026 Truist Securities MedTech Conference in Boston, MA. Management will be hosting a fireside chat on Tuesday, June 16, 2026, at 5:40 a.m. Pacific Time/ 8:40 a.m. Eastern Time. Investors interested in listening to the confere